Hosted on MSN3m
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
That includes $3.5 billion for type 2 diabetes drug Mounjaro and $1.9 billion for the weight-loss drug Zepbound. Every element missed Wall Street's forecast. But Leerink Partners analyst David ...
Stock market today: Asian stocks mixed ahead of US inflation data
Asian stocks are mixed after Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...